The principal investigators for the study are Dean Tang, associate professor of division of carcinogenesis and adjunct associate professor of college of pharmacy at The University of Texas and David Brown, director of discovery from Mirna.
Matt Winkler, CEO of Mirna, said: “We are excited about the therapeutic collaboration with M D Anderson. Combining M D Anderson’s extensive knowledge of prostate cancer biology with Asuragen’s expertise using miRNA with therapeutic potential could lead to improved treatment options for prostate cancer.”